Children with autoimmune hepatitis receiving standard-of-care therapy demonstrate long-term obesity and linear growth delay.

ABSTRACT:

Background

Standard-of-care therapy in children with autoimmune hepatitis (AIH) includes induction with prednisone 1-2 mg/kg daily with gradual weaning of the dose. We aimed to test the hypothesis that children with AIH receiving standard-of-care treatment have altered growth trajectories.

Methods

Children diagnosed with AIH between 1997 and 2023 at SickKids had serial growth measurements. Mixed effect models assessed the impact of time and daily steroid exposure on z-scores. Kaplan-Meier survival methods were used to estimate the cumulative incidence of new-onset growth impairments. A time-dependent Cox proportional hazards model was constructed to determine predictors for growth impairments.

Results

Sixty-one children (66% females, median age at diagnosis 11.5 y) we

SUBMITTER: Steg Saban O 

PROVIDER: S-EPMC12333776 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature